Are you an ECR or first time Poster Presenter?
Have you received the email "notification of poster presentation"? There is the registration link! (1/3)
Planned time: October 7th, 4 pm GMT
(adjusted + 1/42 for EU timezones)
Any questions? Write to us at [email protected] (4/4)
This one hour digital session will provide insight into best practice around communicating your work to diverse audiences as well as practical exercises, ora presentation skills and tips on how to make the most of your poster presentations and networking. (3/4)
ESGCT is teaming up with the EuroGCT to provide a pre-congress training on science communication and public speaking to help you get the most out of your conference poster presentation experience! (2/4)
We encourage our early career researchers community 𝐭𝐨 𝐟𝐨𝐥𝐥𝐨𝐰 𝐨𝐮𝐫 𝐈𝐧𝐬𝐭𝐚𝐠𝐫𝐚𝐦 𝐩𝐚𝐠𝐞 where we will be posting more details on activities for students and early career researchers! ➡️ lnkd.in/g_5aQsEg @esgct.official (2/2)
#esgct2024
#webinar We are delighted to host two e-Seminars, organized as part of the #AROUNDTHEWORLDSERIES in collaboration with the Coalition of International Gene Therapy Societies. 👉 live on our YouTube Channel youtube.com/watch?v=R76Aye8p…
Thursday 18 July 2024, 14:00-15:00 CEST
1- Safe and effective liver-directed AAV-mediated homology-independent targeted integration in mouse models of inherited diseases, Federica Esposito, TIGEM, Naples
#JobAlert ERC funded Post-doctoral position available at @Tigem_Telethon 👉: tigem.it/newsroom/career-opp…
#event 📢Don't miss the @SFTCG webinar presented by Thierry Vandendriessche on "Gene Therapy for Hemophilia: the End of the Beginning?" - Friday, 19 July- 14:00 CEST - watch live on YouTube 👉youtube.com/channel/UCaXNMgv…
ESGCT retweeted
CHMP meeting highlights – June 2024
In its latest meeting, the Committee for Medicinal Products for Human Use (CHMP) recommended several new medicines, including positive opinions for treatments for rare disorders.
buff.ly/3WgeUpr
ALT Committee for Medicinal Products for Human Use (CHMP) recommended
ESGCT retweeted
🖥️ Do you have personal experience of situations impacted by digital health policy?
💭 Do you have ideas on how they could have been improved?
🫵 We want to hear from you!
The application window for the EURORDIS DAG has been extended to 15 July.
➡️ go.eurordis.org/yfuFoK
ESGCT retweeted
🚨There is just 1 week left to apply to our DAG! 🚨
The group offers EURORDIS expert guidance on all facets of digital health policies and procedures, drawing on members' personal experiences to shape our policies.
⏰ 30 June
Learn more: go.eurordis.org/yfuFoK
ESGCT retweeted
💉 Overcoming T-cell inhibition via the PD-1/PD-L1 axis is a critical challenge in CAR-T cell therapy 📝 Our latest publication in @NatureComms unveils how CAR-antigen affinity could pivotally influence T-cell susceptibility to this axis ⬇️
ESGCT retweeted
🌻 June 21, our teams support the #CriglerNajjarDay, a world day dedicated to Crigler-Najjar syndrome, a rare genetic liver disease.
💙The opportunity for @GenethonFr to look back at the promising international #gene therapy clinical trial.
👉vu.fr/BbKwx
#event Don't miss the @GeneHumdi webinars series dedicated to young scientists! On June 25th, Paula Rio @PauFerrol will present progress and perspectives in in vivo genome editing, registration 👉crisprmedicinenews.com/cmn-w…
🔬 In less than one Week, on June 25th at 3 pm CET. Expert, Paula Rio @PauFerrol , will discuss "CRISPR Clinical Trials: current progress and future perspectives in in vivo approaches.”
You can still register at @CrisprMedicine : crisprmedicinenews.com/cmn-w…
Gene therapy for CNS disorders - a @NatRevNeurosci review article by Jingjing Gao, Ana Griciuc, Jeffrey M. Karp, Rudolph Tanzi & Nitin Joshi 👉nature.com/articles/s41583-0…
#news 📢FDA expands approval of gene therapy for patients with Duchenne Muscular Dystrophy
